Biotech
-
Eyes on DIAGNOS as commercialization gains momentum
The best time to buy an emerging company is when it begins commercialization. At this stage all the…
-
Patient Heal Thyself.
Many, many years ago I worked in the crude oil marketing business with a gentleman (and I use…
-
Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
-
Awakn announces first-ever study investigating ketamine in gambling addiction treatment
When we think about addiction many people think about drugs, tobacco, and alcohol addiction; but often forget about…
-
Tremendous technologies all based around Molecular Imprinted Polymers have investors riding the Sixth Wave
Sixth Wave continues to achieve outstanding results at detecting COVID-19 as well as the extraction of cannabinoids, gold…
-
Rritual Superfoods’ next quarterly results could be hard to ignore
If you are a current investor or an interested party in Rritual Superfoods Inc. (CSE: RSF | OTCQB:…
-
Awakn Life Sciences’ Anthony Tennyson on using researched backed psychedelic drugs and therapies to treat Alcohol Use Disorder
In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of Awakn Life Sciences Corp. (NEO:…
-
Element Nutritional Sciences Stuart Lowther on Rejuvenate™ in Walgreens, Aging and the Impact on Muscle Health
In a recent InvestorIntel interview, Tracy Weslosky speaks with Stuart Lowther, President, CEO and Founder of Element Nutritional…
